Cell Microarray data in regulatory submissions

Data from Retrogenix specificity studies have been included in numerous regulatory applications, often instead of tissue cross reactivity studies. In order to help understand the wider impact of Retrogenix specificity assessment, and to quantify the extent to which it is replacing other methods such as tissue cross reactivity (TCR) screening, we have initiated a feedback process which allows us to collate and share data on how recently screened biotherapeutics are progressing. We surveyed pharma, biotech and non-profit sponsors who had undertaken at least one specificity screening project with Retrogenix since mid 2018. The results showed that:

  • Retrogenix screening data have been used in at least 75 regulatory IND submissions. Notably, Retrogenix’s specificity screening data were also included in the licensing application for Novartis’ Kymriah (tisagenlecleucel) which, in 2017, was the first CAR T immunotherapy to receive FDA approval.
  • Retrogenix data is accepted globally; with submissions to the US FDA, EMA (Europe), PMDA (Japan) and NMPA (China).
  • No tissue cross reactivity studies had been performed, in over a third of these submissions (38%) . The data for specificity assessment came solely from Retrogenix studies.
  • 90% of submissions using Retrogenix data have been approved to date*.

*last survey mid-2020

See full survey results


Retrogenix’s high rates of success in target deconvolution, receptor identification and off-target screening are due to:

High Success Rates
Expression in human cells results in correct folding and plasma membrane localisation and allows for multimerisation and the detection of interactions mediated by post-translational modifications such as glycosylation.
At >5,500 full-length clones, our microarrays represent around 80% of 'high confidence' plasma membrane and secreted proteins providing the highest likelihood of identifying a ligand’s specific target.
Full-length, non-fused human proteins are expressed in human cells – a real advantage over traditional protein arrays.
Results delivered in as little as 3 weeks.
Expertise &
Studies are co-designed with clients in order match their needs. Dialogue is maintained throughout and a comprehensive report with data interpretation delivered on completion.
Ligand-receptor interactions around 10 micromolar can be detected even without any amplification strategies. Reproducibility is key, resulting in the detection of specific, biologically-relevant targets.
As the Retrogenix technology detects direct binding of drug to proteins, and is not a competition-based assay, we can discover important allosteric interactions.
Compatible with a range of detection methods including anti-His, anti-Flag, anti-V5, anti-Fc, biotin-streptavidin, directly fluorescently tagged and radiolabeled molecules.

Case Studies

Retrogenix’s results are now supporting patent applications, appearing in peer-reviewed publications and being presented at international conferences.

Find out about how the Retrogenix Technology has been used:

Case Studies


FAQ: “What data will I receive?”

A full report presenting and interpreting the results of the screens is provided at the end of the study. On request, members of the Retrogenix team can also present and discuss the results via a web meeting.

More FAQs

Talk to us about a project
Simcere logo
Aveo Oncology - The Human Response
Theraclone Sciences
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
Sanofi Logo
The University of Copenhagen
Lund University
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
The University of Sheffield
Capella Bioscience Logo
Unum Theraputics Logo
Celyad Logo
I have greatly enjoyed working with you all on this project, it ran seamlessly and I am grateful for the responsiveness, communication and high-quality work from your team. I would not hesitate to perform studies in the future, and will highly recommend Retrogenix to my colleagues for their research needs.
Kathy Whiteman, Senior Scientist, Unum Theraputics